Release Date: November 29, 2023
Expiration Date: November 29, 2024
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in pulmonary arterial hypertension (PAH). In this educational program, these experts discuss the most current risk-assessment strategies and therapies for patients with PAH.
This educational activity is an archive of the live symposium held on November 15, 2023.
Target Audience
This educational activity is directed toward pulmonologists, internists, nurse practitioners, physician assistants, nurses, and other health care providers involved in the management of PAH.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the pathogenic mechanisms surrounding PAH
- Apply guideline-based risk-assessment strategies to individualize care for patients with PAH
- Summarize evidence regarding current and emerging approaches to pharmacologic therapy for PAH
Richard Channick, MD
Saul Brandman Chair in Pulmonary Arterial Hypertension
Co-Director, Pulmonary Vascular Disease Program
UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA
Disclosures: Consultant: Aria CV, Gossamer, Janssen, Liquidia, Respira, Third Pole; Speaker: Bayer, Janssen; Researcher: Aria CV
Josanna Rodriguez-Lopez, MD
Director of Pulmonary Hypertension and CTEPH Program
Assistant Professor, Harvard Medical school
Division of Pulmonary and Critical Care Medicine
Massachusetts General Hospital
Boston, MA
Disclosures: Researcher: Bayer, Janssen, Merck, United Therapeutics; Consultant: Altavant Sciences, Bayer, Janssen, Merck, Third Pole, United Therapeutics.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
